Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2007-05-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMCL.2007.03.003PMID 17368897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methicillin-ResistantStaphylococcus aureus in Europe

  2005cited by this paper
• Catalytic asymmetric total syntheses of quinine and quinidine.

  2004cited by this paper
• Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong

  1999cited by this paper
• Patents on DNA gyrase inhibitors: January 1995 to March 1998

  1998cited by this paper
• The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X‐ray crystallography.

  1996cited by this paper
• Methicillin-resistant Staphylococcus aureus in Europe.

  1994cited by this paper
• Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones

  1994cited by this paper
• The interaction between coumarin drugs and DNA gyrase

  1993cited by this paper
• DNA gyrase: structure and function.

  1991cited by this paper
• Crystal structure of an N-terminal fragment of the DNA gyrase B protein

  1991cited by this paper
• Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency.

  1990cited by this paper
• ANTIBIOTIC AND CHEMOTHERAPY

  1974cited by this paper

• AI-guided competitive docking for virtual screening and compound efficacy prediction

  2026cites this paper
• Recent advances in the synthesis of anticancer pyrazole derivatives using microwave, ultrasound, and mechanochemical techniques

  2025cites this paper
• AI-guided competitive docking for virtual screening and compound efficacy prediction

  2025cites this paper
• [4+2] Cycloaddition Mediated Stereoselective Synthesis of Tetrahydro‐1H‐Isobenzofuro Chromene Dione Derivatives: Antibacterial Evaluation and Molecular Docking Investigation

  2024cites this paper
• Dynamic Profiling and Binding Affinity Prediction of NBTI Antibacterials against DNA Gyrase Enzyme by Multidimensional Machine Learning and Molecular Dynamics Simulations

  2024cites this paper
• Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance

  2024cites this paper
• Molecular mechanism of a triazole-containing inhibitor of Mycobacterium tuberculosis DNA gyrase

  2024cites this paper
• Synthesis of a Pyridoazepine Scaffold via Rhodium-Catalyzed Ring Expansion and Nitroacetamide Condensation

  2023cites this paper
• The overview of development of novel bacterial topoisomerase inhibitors effective against multidrug-resistant bacteria in an academic environment: from early hits to in vivo active antibacterials.

  2023cites this paper
• Tetrahydroazepines with an annulated five-membered heteroaromatic ring

  2022cites this paper
• A Molecular Insight into Pyrazole Congeners as Antimicrobial, Anticancer, and Antimalarial Agents.

  2022cites this paper
• The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV

  2022cites this paper
• Synthesis of Heterocyclic Systems 3H-furo[2,3-b]imidazo[4,5-f]quinolines and 3H-furo[2,3-b]pyrazolo[4,3-f]quinolines as New Antibacterial Agents

  2022cites this paper
• Discovery of novel 1,3,5‐triazines as potent antibacterial agent against urinary tract infection‐causing clinical isolates of Escherichia coli via inhibition of DNA Gyrase

  2022cites this paper
• Why Matter Matters: Fast-Tracking Mycobacterium abscessus Drug Discovery

  2022cites this paper
• Antimigratory effect of pyrazole derivatives through the induction of STAT1 phosphorylation in A549 cancer cells.

  2021cites this paper
• Novel Bacterial Topoisomerase Inhibitors (NBTIs) – A comprehensive review

  2021cites this paper
• A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus

  2021cites this paper
• Structurally Optimized Potent Dual-Targeting NBTI Antibacterials with an Enhanced Bifurcated Halogen-Bonding Propensity

  2021cites this paper
• A Fine-Tuned Lipophilicity/Hydrophilicity Ratio Governs Antibacterial Potency and Selectivity of Bifurcated Halogen Bond-Forming NBTIs

  2021cites this paper
• Synthesis, Antiviral, Antibacterial, and Cytotoxicity Assessment of Some 3H-Benzo[a]imidazo[4,5-j]acridines and 3H-Benzo[a]pyrazolo[3,4-j]acridines

  2020cites this paper
• Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.

  2020cites this paper
• Yeast: A Model Organism for Antimicrobial Drug Discovery

  2020cites this paper
• Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs)

  2020cites this paper
• Synthetic Methods and Antimicrobial Perspective of Pyrazole Derivatives: An Insight

  2020cites this paper
• Synthesis of N,N′-bis(1,5-dimethyl-2-phenyl-1,2-dihydro-3-oxopyrazol-4-yl) sebacamide that ameliorate osteoarthritis symptoms and improve bone marrow matrix structure and cartilage alterations induced by monoiodoacetate in the rat model: “Suggested potent anti-inflammatory agent against COVID-19”

  2020cites this paper
• Cyclohexyl amide-based novel bacterial topoisomerase inhibitors with prospective GyrA-binding fragments.

  2019cites this paper
• The Novel Synthesis of Functionalized Indenopyrazolones Using Fe 3 O 4 nanoparticles stabilized on MMT: An Efficient Magnetically Recoverable Heterogeneous Nanocomposite Catalyst

  2019cites this paper
• Discovery of Novel Triazole-Containing Pyrazole Ester Derivatives as Potential Antibacterial Agents

  2019cites this paper
• Synthesis and Antibacterial Evaluation of New2‐Phenylbenzimidazole Derivatives

  2019cites this paper
• Virtual Screening Approach and Investigation of Structure Activity Relationships to Discover Novel Bacterial Topoisomerase Inhibitors (NBTIs) Targeting Gram-Positive and Gram-Negative Pathogens.

  2019cites this paper
• 1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition.

  2019cites this paper
• Bacterial Type II Topoisomerases and Target-Mediated Drug Resistance

  2018cites this paper
• Topoisomerases as anticancer targets.

  2018cites this paper
• The Macromolecular Machines that Duplicate the Escherichia coli Chromosome as Targets for Drug Discovery

  2018cites this paper
• Novel bacterial topoisomerase inhibitors: challenges and perspectives in reducing hERG toxicity.

  2018cites this paper
• Four Ways to Skin a Cat: Inhibition of Bacterial Topoisomerases Leading to the Clinic

  2017cites this paper
• DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens

  2017cites this paper
• Structure-based design of novel combinatorially generated NBTIs as potential DNA gyrase inhibitors against various Staphylococcus aureus mutant strains.

  2017cites this paper
• Synthesis and Characterization of Tetrahydropyran-Based Bacterial Topoisomerase Inhibitors with Antibacterial Activity against Gram-Negative Bacteria.

  2017cites this paper
• Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

  2017cites this paper
• In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase

  2016cites this paper
• Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions.

  2016cites this paper
• Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.

  2016cites this paper
• Optimized Synthesis of Novel Pyrazole Based Thiazole Derivatives and their Antimicrobial Evaluation

  2016cites this paper
• Synthesis and Characterization of Novel 1,2,4‐oxadiazoline Derivatives Containing Pyrazole Moiety by 1,3‐Dipolar Cycloaddition

  2016cites this paper
• Yeast: a microbe with macro-implications to antimicrobial drug discovery.

  2016cites this paper
• Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4).

  2015cites this paper
• Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).

  2015cites this paper
• Synthesis of 3,5-Disubstituted-1H-Pyrazoles from Acid Chlorides, Alkynes, and Hydrazine in the Presence of Silica-Supported-Zinc Bromide

  2015cites this paper
• Mode of action of closthioamide: the first member of the polythioamide class of bacterial DNA gyrase inhibitors.

  2015cites this paper
• Synthesis of New Macrocyclic Schiff Bases Containing Pyrazole and Triazole as Subcyclic Units

  2015cites this paper
• Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).

  2015cites this paper
• Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6).

  2015cites this paper
• Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).

  2015cites this paper
• C1–C2-linker substituted 1,5-naphthyridine analogues of oxabicyclooctane-linked NBTIs as broad-spectrum antibacterial agents (part 7)

  2015cites this paper
• Evidence for the contribution of non-covalent steroid interactions between DNA and topoisomerase in the genotoxicity of steroids

  2015cites this paper
• Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism.

  2014cites this paper
• Design, synthesis, docking study & antibacterial evaluation of 1,3-Ddiarylpyrazolyl substituted Indolin-2-ones

  2014cites this paper
• Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

  2014cites this paper
• Confronting the challenges of discovery of novel antibacterial agents.

  2014cites this paper
• Discovery of 7‐Aryl‐Substituted (1,5‐Naphthyridin‐4‐yl)ureas as Aurora Kinase Inhibitors

  2014cites this paper
• Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents.

  2014cites this paper
• Synthesis, and antibacterial activity of novel 4,5-dihydro-1H-pyrazole derivatives as DNA gyrase inhibitors.

  2014cites this paper
• Recent Developments in Inhibitors of Bacterial Type IIA Topoisomerases

  2013cites this paper
• Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.

  2013cites this paper
• A facile access to 1,3,4-trisubstituted pyrazoles via 1,3-dipolar cycloaddition of 3-arylsydnones with α,β-unsaturated ketones

  2013cites this paper
• Pyrazole derivatives as antitumor, anti-inflammatory and antibacterial agents.

  2013cites this paper
• Designing type II topoisomerase inhibitors: A molecular modeling approach.

  2013cites this paper
• Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.

  2013cites this paper
• Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.

  2013cites this paper
• IN-VITRO INHIBITION STUDIES ON ENDOGENOUS PROTEOLYSIS OF LIVER HOMOGENATE IN PRESENCE OF SYNTHESIZED PYRAZOLINES

  2013cites this paper
• De novo design of novel DNA-gyrase inhibitors based on 2D molecular fingerprints.

  2013cites this paper
• Facile synthesis of stable isotope‐labeled antibacterial agent RWJ‐416457 and its metabolite

  2012cites this paper
• Architecture and Conservation of the Bacterial DNA Replication Machinery, an Underexploited Drug Target

  2012cites this paper
• Allosteric inhibition of the DNA-dependent ATPase activity of Escherichia coli DNA gyrase by a representative of a novel class of inhibitors.

  2012cites this paper
• Highly efficient thermal cyclization reactions of alkylidene esters in continuous flow to give aromatic/heteroaromatic derivatives

  2012cites this paper
• Bacterial DNA replication enzymes as targets for antibacterial drug discovery

  2012cites this paper
• Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors.

  2011cites this paper
• N-Benzyl-3-sulfonamidopyrrolidines are a New Class of Bacterial DNA Gyrase Inhibitors.

  2011cites this paper
• Synthesis and antimicrobial activity of some new 4-hetarylpyrazole and furo[2,3-c]pyrazole derivatives.

  2011cites this paper
• Exploiting bacterial DNA gyrase as a drug target: current state and perspectives

  2011influential citation
• The Medicinal Chemistry of Tuberculosis Chemotherapy

  2011cites this paper
• Challenges of Antibacterial Discovery

  2011cites this paper
• Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.

  2011cites this paper
• ADMEt Evaluation of Anti-tuberculosis Compounds and New Methodologies Development

  2011cites this paper
• Resolution, absolute configuration, and synthetic transformations of 7-amino-tetrahydroindazolones

  2011cites this paper
• Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases.

  2011cites this paper
• Advances in structure-based drug design of novel bacterial topoisomerase inhibitors.

  2010cites this paper
• In front of and behind the replication fork: bacterial type IIA topoisomerases

  2010cites this paper
• An overview of conventional and alternative strategies for developing new antibacterial agents.

  2010cites this paper
• Fragments of microcin B17 as a source of new topoisomerase inhibitors

  2010cites this paper
• Possible structural and functional determinants contributing to the clastogenicity of pharmaceuticals

  2010cites this paper
• Type IIA topoisomerase inhibition by a new class of antibacterial agents

  2010cites this paper
• Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.

  2009cites this paper
• One hundred years of Meldrum’s acid: advances in the synthesis of pyridine and pyrimidine derivatives

  2009cites this paper
• Synthesis of triazole-functionalized tetrahydroindazolones by 1,3-dipolar cycloadditions between azides and alkynes

  2009cites this paper
• Utility of p‐phenylenediformamidine in the synthesis of bisazoles and phenanthroline

  2009cites this paper
• Synthesis, structure and antibacterial activity of novel 1-(5-substituted-3-substituted-4,5-dihydropyrazol-1-yl)ethanone oxime ester derivatives.

  2008cites this paper
• Recent advances in bacterial topoisomerase inhibitors.

  2008cites this paper